European researchers have identified two microRNAs, or small non-coding RNA molecules, that can be used to predict outcomes of malignant pleural mesothelioma, in an international study that…
Cell Medica will begin manufacturing WT1-TCR cell therapy for solid tumors that have been difficult to treat with conventional therapies, such as mesothelioma and ovarian cancer. Cell…
The point at which doctors assess biomarkers of mesothelioma patients’ response to a combination of chemotherapy and immunotherapy is crucial to obtaining a clear picture of…
Even though 40 years have passed since their exposure to asbestos, workers’ risk of developing mesothelioma continues to rise, new research shows. Individuals exposed to asbestos four decades ago…
A new study reports that a protein formerly identified as a potential therapeutic target in pleural mesothelioma, CXCR4, might not be a relevant approach for the…
A study that looked into France’s RENAPE Observational Registry, a database of rare peritoneal tumors, found that the presence of programmed death-ligand 1 (PD-L1) on…
Combining immunotherapy, accelerated radiation and surgery can improve immune system response against malignant pleural mesothelioma, according to a study. Immunotherapies for solid tumors have become a…
Activating a new mechanism to promote cell death could provide hope for better mesothelioma treatments, a Japanese study indicates. The research, ”Connexin 43 enhances Bax…
Zoledronic acid was only modestly active as a stand-alone therapy for advanced malignant pleural mesothelioma in a small Phase 2 pilot clinical trial. But researchers…
A key approach to treating cancer these days is engineering immune T-cells to produce receptors on their surfaces that recognize cancer, so that the T-cells…